YOU ARE HERE: LAT HomeCollectionsBiotechnology Companies

Biotechnology Companies

October 31, 2008 | R. Jeffrey Smith, Smith writes for the Washington Post.
The White House is working to enact an array of federal regulations, many of which would weaken rules aimed at protecting consumers and the environment, before President Bush leaves office in January. The new rules would be among the most controversial deregulatory steps of the Bush era and could be difficult for his successor to undo. Some would ease or lift existing constraints on private industry, including power plants, mines and farms.
May 2, 2007 | From Reuters
Genentech Inc. and Biogen Idec Inc. said their Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potential new way of treating the progressive neurological disease. The biotechnology companies said the Phase II trial involved 104 patients with the most common "relapsing-remitting" form of multiple sclerosis -- in which patients have varying levels of recovery and periods of remission between flare-ups of the autoimmune disease.
March 17, 2013
One of the most promising frontiers in healthcare is biologic medicines - complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies what amounts to a 12-year monopoly on the substances they developed. Now, supporters of biologics are pushing lawmakers in Sacramento and other state capitals to put new hurdles in the way of knock-off compounds, called "biosimilars. " The debate over biosimilars is grounded in doubts about their safety; none have yet been approved for use in the United States.
October 4, 2002 | From Times Wire Reports
The government has created a genetically engineered anthrax vaccine that promises to cut in half the six shots now needed for protection, and chosen two biotechnology companies to begin testing it. The $22.5-million contract award will allow California-based VaxGen Inc. and Britain's Avecia to test the experimental vaccine on people to see if it is safe and, if so, to see if it provides protection against the deadly bacteria.
August 29, 2006 | From Reuters
Biotechnology companies Genentech Inc. and Biogen Idec Inc. said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial. The study involved 104 adults with the most common form of multiple sclerosis. It showed a statistically significant reduction among those given Rituxan in the total number of brain lesions, South San Francisco-based Genentech said. Rituxan is one of the biggest-selling treatments for non-Hodgkin's lymphoma.
June 14, 1985
The Rockville, Md., biotechnology firm said its contract to produce ingredients for Searle's popular sweetener, aspartame, will not be renewed when it expires Oct. 31. Genex has often been listed as one of the nation's five most promising biotechnology companies. Its sales to Searle in 1984 accounted for $20.2 million of Genex's product sales of $20.6 million and 58% of the company's total revenue of $34.8 million. Both companies declined to comment on why the contract will not be extended.
Los Angeles Times Articles